[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genetic-testing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genetic-testing":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,63,87,120,151,177,200,223,246,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":38,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100635793","supporting-just-in-time-consent-for-prenatal-screening-the-inform-study-100635793",false,"NCT07557303","Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study","Inclusion Criteria:\n\n* Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.\n* 18 years of age and older\n* Able to read, speak, and understand English or Spanish\n* Has not previously been offered prenatal genetic screening for the current pregnancy\n* 24 weeks (6 months) gestational age or less\n\nExclusion Criteria:\n\n* Not pregnant, not a patient at a partner clinical site\n* Younger than 18 years of age\n* Not being able to read, speak, and understand English or Spanish\n* Has previously been offered prenatal genetic screening for the current pregnancy\n* Greater than 24 weeks gestational age (6 months)",true,"FEMALE","18 Years",{"count":19,"type":20},1400,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.\n\nThe study has one main question:\n\n* Do participants who use the intervention feel more confident when they make a decision about screening?\n\nResearchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.\n\nWhat will participants do?\n\n* Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.\n* Some participants will use the intervention before their first doctor's visit. Other participants will not use it.\n* All participants will talk with a researcher on the phone after their first doctor's visit.\n* Participants who use the intervention will answer a short survey on their phone.\n* A few participants who use the intervention will talk with a researcher a second time on the phone.",[26,27,28,29,30,31,32,33,34,35,36,37],"Delivery of Health Care","Genetic Testing","Humans","Pregnancy","Noninvasive Prenatal Testing","Informed Consent","Internet-Based Intervention","Self Efficacy","Pregnant People","Decision Making","Health Education","Patient Education as Topic\u002FMethod",[39,40,41,42,43,44,45,46,47,48,49],"Non-invasive prenatal screening (NIPS)","Non-Invasive Prenatal Testing (NIPT)","Cell-free DNA (cfDNA)","Prenatal genetic screening","Informed consent","Decision making","Surveys and Questionnaires","Informed choice","Educational intervention","Decision Regret","Decision Satisfaction","NOT_YET_RECRUITING","2026-06-30",{"date":53,"type":54},"2026-07-01","ACTUAL",{"date":56,"type":20},"2026-08-01",{"date":58,"type":20},"2028-06-30",{"name":60,"class":61},"Case Western Reserve University","OTHER",3,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100599870","pitch---impacting-hereditary-cancer-testing-100599870","NCT07090109","PITCH - Impacting Hereditary Cancer Testing","Partnering to Impact Testing in the Commonwealth for Hereditary Cancers (PITCH)","Inclusion Criteria:\n\n* diagnosed with a cancer that can be associated with hereditary forms of cancer\n\nExclusion Criteria:\n\n* previously undergone multi-gene panel testing for hereditary cancers",{"count":71,"type":20},200,[23],"The goal of this clinical trial is to assess patients' knowledge and attitudes about genetic testing before and after viewing an educational video. The main questions it aims to answer are:\n\n* Did the video change participants' knowledge and attitudes about genetic testing?\n* Did participants make an informed choice about pursuing genetic testing?\n\nParticipants will:\n\n* Complete a baseline survey\n* View educational video\n* Complete follow-up survey",[75,27,76],"Ovarian Cancer","Genetic Counseling","2026-06-22",{"date":79,"type":54},"2026-06-25",{"date":81,"type":20},"2026-08",{"date":83,"type":20},"2027-07",{"name":85,"class":61},"Rachel Miller",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":17,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100637829","expanding-genetic-access-for-prostate-cancer-survivors-100637829","NCT07618520","Expanding Genetic Access for Prostate Cancer Survivors","Expanding Genetic Access and Guided Education for Prostate Cancer Survivors","ENGAGE","Inclusion Criteria:\n\n* 18-80 years of age\n* At least 6-months post diagnosis with prostate cancer\n* Have not had genetic testing for hereditary cancer\n* Have received care at one of the participating sites in the prior five years\n* Meet National Comprehensive Cancer Network criteria for germline GT\n* Able to read and speak in English\n* Capable of providing informed consent\n* Have internet access (via smartphone, tablet or computer)\n* Comfortable using a computer or mobile phone independently to access information\n\nExclusion Criteria:\n\n* Do not speak English\n* Unable to access the Internet\n* Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)\n* Are unable to provide informed consent","MALE","80 Years",{"count":98,"type":20},500,[23],"The goal of this study is to increase genetic education and genetic testing for hereditary cancer risk among prostate cancer survivors. The study will:\n\nTest the effectiveness of a digital guide (DG+) vs. print guide (Print+) vs. enhanced usual care (EUC) on engagement in genetic education and uptake of genetic testing.\n\nEvaluate the impact of the DG+ vs. Print+ vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes).\n\nExplore the ways (methods) that influence how participants experience the intervention.\n\nThe main questions this study aims to answer are: which group - the digital guide (DG+) group, print (Print+) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education.\n\nParticipants will be randomly assigned to either the digital guide (DG+) group, the print guide (Print+) group or EUC group. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the three groups to determine which is most most likely to complete genetic testing (GT) and which group engages more with genetic education.",[102,103,27],"Prostate Cancer Patients","Hereditary Cancer",[105,106,107,108,109,110],"Prostate cancer","survivorship","genetic counseling","genetic testing","hereditary cancer","Chatbot","2026-05-25",{"date":113,"type":54},"2026-06-01",{"date":56,"type":20},{"date":116,"type":20},"2030-07-31",{"name":118,"class":61},"Georgetown University",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":140,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":86},"100456579","video-education-with-result-dependent-disclosure-100456579","NCT05225428","Video Education With Result Dependent dIsclosure","VERDI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma\n* Ability to understand spoken or written English or Spanish in a healthcare context\n* Ability to understand and the willingness to sign a written informed consent document\n* Black or Latinx (qualitative assessment study only)\n\nExclusion Criteria:\n\n* Prior cancer genetic testing\n* Prior germline genetic testing\n* Active hematologic malignancy (e.g. chronic lymphocytic leukemia)\n* Currently pregnant\n* Currently incarcerated","ALL",{"count":129,"type":20},1020,[23],"The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.",[27,133,75,134,135,136,137,138,139],"Breast Cancer","Pancreatic Cancer","Prostate Cancer","Colorectal Cancer","Renal Cancer","Melanoma","Sarcoma",[27,133,75,134,135,136,137,138,139],"RECRUITING","2026-05-20",{"date":144,"type":54},"2026-05-22",{"date":146,"type":54},"2022-08-04",{"date":148,"type":20},"2026-10-01",{"name":150,"class":61},"Dana-Farber Cancer Institute",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100316190","responses-to-genetic-risk-modifier-testing-among-women-with-pathogenic-variants-in-breast-cancer-predisposition-genes-100316190","NCT03396341","Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes","Inclusion Criteria:\n\nPhase I:\n\n* Female patient, age 25 years or older (given that women under this age are not generally recommended to receive BRCA1\u002F2 genetic testing)\n* Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified\n* No personal history of breast cancer\n* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.\n\nPhase 2:\n\n* Female sex\n* Completed germline genetic testing with one clinically confirmed pathogenic\u002Flikely pathogenic variant in either of the following genes and with the associated age minimums:\n\n  * BRCA1 and currently age 25 years or older\n  * BRCA2 and currently age 25 years or older\n  * ATM (all pathogenic\u002Flikely pathogenic variants EXCEPT for the variant ATM c.7271T\\>G \\[p.Val2424Gly\\]) and currently age 30 years or older\n  * CHEK2 (all pathogenic\u002Flikely pathogenic variants EXCEPT for the variants CHEK2 c.470T\\>C \\[p.Ile157Thr ; I157T\\] and CHEK2 c.1283C\\>T\\[p.Ser428Phe ; p.S428F\\] and CHEK2 c.1427C\\>T \\[p.Thr476Met\\]) and currently age 30 years or older\n  * PALB2 and currently age 30 years or older\n* No personal history of breast cancer\n* English-fluent based on self-report or the EMR; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.\n\nExclusion Criteria:\n\nPhase I:\n\n* Previous receipt of any prophylactic mastectomy.\n* Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.\n* Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.\n\nPhase 2:\n\n* Previous receipt of any prophylactic mastectomy.\n* Major untreated psychiatric illness or cognitive impairment that would preclude study participation.\n* Any patients who participated and received genetic risk modifier test results from Phase 1 of this protocol.","25 Years",{"count":159,"type":20},806,"OBSERVATIONAL","The purpose of this study is to describe how women with BRCA1\u002F2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.",[27,163],"BRCA1\u002F2",[165,166],"BRCA1\u002F2 Mutations","17-489","2026-05-15",{"date":169,"type":54},"2026-05-19",{"date":171,"type":54},"2018-01-04",{"date":173,"type":20},"2027-01",{"name":175,"class":61},"Memorial Sloan Kettering Cancer Center",7,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":86},"100262136","genes-associated-with-development-of-pulmonary-arterial-hypertension-in-patients-with-congenital-shunt-lesions-100262136","NCT02691689","Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions","Prospective, Monocentric Pilot Study for the Identification of Known or Novel Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions","Inclusion Criteria:\n\n* Previous diagnosis of secundum atrial septal defect (ASD) or ventricular septal defect (VSD), with or without repair\n* Development of PAH, defined as mean PAP ≥ 25 mmHg by right heart catheterization, in combination with a pulmonary wedge pressure of ≤ 15 mmHg and a PVR (pulmonary vascular resistance) of \\> 3 Wood units\n* Preferably, families with congenital shunt lesions (at least three family members affected with ASD or VSD) will be considered for inclusion\n\nExclusion Criteria:\n\n* Other congenital heart disease\n* Mental retardation\n* Dysmorphic characteristics\n* Chronic lung disease or total lung capacity \\\u003C 80% of predicted value\n* History of pulmonary embolism",{"count":185,"type":20},21,[23],"Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is associated with considerable morbidity and even mortality.\n\nNext to environmental risk factors, the investigators believe that there is an important role of genetic predisposition to develop PAH in CHD. There often is a discrepancy between the severity of PAH and the CHD, where it is useful to screen for PAH gene mutations. The investigators hypothesize that the genotype is partly responsible for the phenotypic variability in patients with congenital shunt lesions, where some develop PAH and others do not. If a genetic predisposition for PAH in CHD could be identified, then genetic screening could be a useful additional tool for early detection of patients at risk of pulmonary vascular disease and PAH development, with new opportunities for prevention or early treatment.",[189,190,27],"Heart Defects, Congenital","Pulmonary Arterial Hypertension","2026-04-27",{"date":193,"type":54},"2026-04-29",{"date":195,"type":54},"2015-11",{"date":197,"type":20},"2027-02",{"name":199,"class":61},"Universitaire Ziekenhuizen KU Leuven",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":127,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":86},"100466041","comparing-direct-vs-indirect-methods-for-cascade-screening-100466041","NCT05348564","Comparing Direct vs Indirect Methods for Cascade Screening","Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)","Proband Inclusion Criteria:\n\n* KCNQ1 Thr224Met or APOB R3527Q carrier\n* 18 years or older\n\nProband Exclusion Criteria:\n\n* None\n\nFamily Inclusion Criteria:\n\n* 1st degree relative of a KCNQ1 Thr224Met or APOB Arg3527Gln carrier\n\nFamily Exclusion Criteria:\n\n* None",{"count":71,"type":20},[23],"An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes.\n\nIndividuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.",[211,212,213,27],"Long QT Syndrome","Familial Hypercholesterolemia","Ethics","2026-04-10",{"date":216,"type":54},"2026-04-14",{"date":218,"type":54},"2023-05-15",{"date":220,"type":20},"2027-10",{"name":222,"class":61},"University of Maryland, Baltimore",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":15,"sex":16,"minAge":157,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":86},"100587317","universal-genetic-testing-for-cancer-risk-reduction-100587317","NCT06926816","Universal Genetic Testing for Cancer Risk Reduction","Inclusion Criteria:\n\n1. Female patients between ages of 25-39 years at the time of visit\n2. Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol.\n\nExclusion Criteria:\n\n1. Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers\n2. Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable)\n3. History of bilateral salpingo-oophorectomy\n4. Visit related to pregnancy or immediately postpartum (within 2 weeks)","39 Years",{"count":231,"type":20},600,[23],"The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.",[27],[236],"Cancer","2026-02-27",{"date":239,"type":54},"2026-03-02",{"date":241,"type":54},"2025-03-04",{"date":243,"type":20},"2027-12-31",{"name":245,"class":61},"NYU Langone Health",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":15,"sex":127,"minAge":17,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":86},"100616763","improving-genetic-medicine-for-ethnic-minority-groups-100616763","NCT07309835","Improving Genetic Medicine for Ethnic Minority Groups","Capturing Ethnic Minority Experiences of Genomic Pathways to Understand What Changes Are Needed to Promote Greater Equity Within the Genomic Medicine Service.","Inclusion Criteria:\n\n* Adults\n* Have capacity to consent to take part\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Affected by a serious mental health condition\n* Learning disabilities",{"count":254,"type":20},100,"A key aim of the nationally commissioned Genomic Medicine Service (GMS) in England is to encourage equity of access between different patient groups, however, there is evidence to suggest that it is being under-utilised by ethnic minority groups. The aim of this study is to explore how ethnic minority populations interact with the GMS and to identify changes that would promote equity within those services.\n\nThis is a mixed-methods study using interviews and group discussions with lay people, community organisers and charity workers, people who have had direct or indirect contact with the genomic medicine service and professionals within the service. By including potential service users, service users and professionals in this work and allowing people to share their experiences in whatever method feels most comfortable to them, we aim to get a broad understanding of the lived experience of everyone involved in these pathways which will be key to gaining a holistic understanding of how they are working in real world settings.\n\nThe primary outcome measure will be an increased understanding of the experiences of people from ethnic minority groups navigating the genomic medicine space. The secondary outcome measure will be an increased understanding of how experiences differ across and between ethnic groups. We intend to use our insights to recommend structural changes which will improve utilisation of the genomic medicine service by patients from ethnic minority groups.",[27],[258,259,260,261,108,262],"interview","ethnic minority","mixed method","qualitative","genomic testing","2025-12-16",{"date":265,"type":54},"2025-12-30",{"date":267,"type":20},"2026-01-30",{"date":269,"type":20},"2031-01-30",{"name":271,"class":61},"Guy's and St Thomas' NHS Foundation Trust",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":15,"sex":127,"minAge":17,"maxAge":96,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":119},"100521748","addressing-genomic-disparities-in-cancer-survivors-100521748","NCT06073626","Addressing Genomic Disparities in Cancer Survivors","Inclusion Criteria:\n\n* 18-80 years of age\n* Self-identify as Black or African American\n* At least 6-months post diagnosis with any of the following cancers: breast, ovarian, uterine, prostate, colorectal, pancreatic\n* Have not had genetic testing for hereditary cancer\n* Have received care at one of the participating sites in the prior five years\n* Meet National Comprehensive Cancer Network criteria for germline GT\n* Able to read and speak in English\n* Capable of providing informed consent\n* Have internet access (via smartphone, tablet or computer)\n* Comfortable using a computer or mobile phone independently to access information\n\nExclusion Criteria:\n\n* Do not speak English\n* Unable to access the Internet\n* Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)\n* Are unable to provide informed consent",{"count":279,"type":20},428,[23],"The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will:\n\n1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic education and requests for genetic testing.\n2. Evaluate the impact of the chatbot vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes).\n3. Explore the ways (methods) that influence how participants experience the intervention.\n4. Explore the feasibility of incorporating a Family Sharing Portal (FSP) for participants who receive a positive test result, to facilitate family communication of these test results and genetic testing of first-degree biological relatives after they have received genetic education by the RA.\n\nThe main questions this study aims to answer are which group - the chatbot (RA) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education.\n\nParticipants will be randomly assigned to either the chatbot (RA) group or EUC group. This means each participant has an equal chance of being placed in either group, just like flipping a coin. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the chatbot (RA) group and the EUC group to see which may request more GT (genetic testing) and which group engages more with genetic education.",[103,27],[109,108,284,285,286],"genetic education","relational agent","chatbot","2025-10-24",{"date":289,"type":54},"2025-10-28",{"date":291,"type":54},"2024-07-31",{"date":293,"type":20},"2027-08-31",{"name":295,"class":61},"Rutgers, The State University of New Jersey"]